Exact Therapeutics AS. (1/29/21). "Press Release: Exact Therapeutics Announces Change of CFO with Departure of Stig Jarle Pettersen at the End of His Contracted Period". Oslo & London.

	Organisation	Exact Therapeutics AS
	Product	Acoustic Cluster Therapy (ACT® sonoporation)
	Product 2	financial services
	Person	Hayhurst, Richard F. (Richard Hayhurst Associates 202108 before Hayhurst Media 200705)
	Person 2	Hasan, Rafiq (Complement Therapeutics 202202– CEO before Exact Therapeutics + Bayer + Novartis)

EXACT THERAPEUTICS AS (“EXACT-Tx” or the “Company”), a clinical stage precision medicine company today announced that the company’s CFO Stig Jarle Pettersen, engaged as a part time consultant via his company CFO For Hire AS, will leave the company on January 31st 2021 at the end of his contracted period. EXACT Tx thanks Stig for his valuable contribution since joining the company in January 2019 and in particular for his support during the successful financing and listing on the Merkur Market (Euronext growth) in July 2020.

The process of hiring a full time CFO is ongoing and Ole Fegth of Abaci AS will assume CFO responsibilities for the company until ad interim.

About ACT®

• ACT® is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent.

ACT® is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration.

• Initial focus of the company is oncology, however the ACT® platform has potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and product classes.

About EXACT

EXACT-Tx is a clinical stage Norwegian biotech company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. www.exact-tx.com

For more information contact:

Dr Rafiq Hasan
CEO EXACT Therapeutics
Rafiq@exact-tx.com

Richard Hayhurst/Janet Joy
Tel +44 7711 821527
richard@rhapr.eu

Record changed: 2023-06-05